Although IFNγ upregulates major histocompatibility complex (MHC) expression and antigen presentation on myeloid cells, in the tumor microenvironment, it is indeed one of the most potent drivers of PD-L1 expression on immune cells and tumor, which can counteract the effects of PD-L1 blocking antibodies, leading to “adaptive resistance” (8, 12). Here, IFNG is linked to neoplasm.